Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality 2023-10-17 08:30
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease 2023-10-02 08:30
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services 2023-08-11 08:30
WuXi Biologics to Increase Manufacturing Capacity in Germany 2023-06-01 16:49
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations 2023-05-22 16:30
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients 2023-05-16 16:00
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability 2023-04-28 14:43
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease 2023-03-28 20:11
WuXi Biologics Reports Remarkable 2022 Annual Results 2023-03-22 20:09
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers 2023-01-05 08:30
WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List 2022-12-16 08:44
WuXi Biologics Provides Corporate Updates 2022-10-27 22:13
WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China 2022-10-26 12:30
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities 2022-10-24 08:30
WuXi Biologics Receives "Best CDMO Award of the Year" 2022-10-14 09:00
WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody 2022-10-12 09:00
WuXi Biologics Co., Ltd. Removed from Unverified List 2022-10-10 07:55
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts 2022-09-29 10:41
WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA 2022-09-20 10:48
WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey 2022-08-31 20:00
1 2 3 4 5 9